Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 20/20 | 0.61 |
| ▸ | JAK1 | P23458 | 17/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31161391 | 1.00 | TYK2 (0.61) | TYK2JAK1KCNH2CYP2C19STAT3 | |
| SCHEMBL30227307 | 0.93 | TYK2 (0.71) | TYK2JAK1CYP2C19STAT3 | |
| SCHEMBL25232915 | 0.93 | TYK2 (0.71) | TYK2JAK1CYP2C19STAT3 | |
| SCHEMBL30393144 | 0.91 | TYK2 (0.63) | TYK2JAK1KCNH2CYP2C19 | |
| SCHEMBL30392752 | 0.91 | TYK2 (0.63) | TYK2JAK1KCNH2CYP2C19 | |
| SCHEMBL24899888 | 0.91 | TYK2 (0.63) | TYK2JAK1KCNH2CYP2C19 | |
| SCHEMBL21013628 | 0.88 | JAK1 (0.59) | TYK2JAK1KCNH2 | |
| SCHEMBL31139563 | 0.88 | JAK1 (0.66) | TYK2JAK1KCNH2 | |
| SCHEMBL24498077 | 0.87 | TYK2 (0.52) | TYK2JAK1KCNH2CYP2C19STAT3 | |
| SCHEMBL29739946 | 0.87 | TYK2 (0.52) | TYK2JAK1KCNH2CYP2C19STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | TYK2 1/4885JAK1 27/4885KCNH2 2569/4885 |
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | JAK3, TYK2, IRAK3 | TYK2 2/4885JAK1 11/4885KCNH2 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.